Management
Guidelines
Portal
DNDF Model
UCD Nutrition Management Guidelines
First Edition
April 2026, v.1.2
Updated: April 2026
Feedback/Comments :: View Release Notes
Send us your Feedback & Comments
Nutrition Recommendations
Question
4. For individuals with UCD, what supplements and pharmacological therapies or medications are associated with positive outcomes?
Conclusion Statement
Derived from evidence and consensus based clinical practice

UCD management relies on pharmacological therapies and targeted amino acid supplementation to optimize metabolic control, protein tolerance, and patient outcomes. Use of nitrogen scavengers are supported by both clinical studies and expert consensus as essential to improve metabolic control and allow for increased protein intake. Scavenger therapy is typically prescribed alongside a protein-restricted diet, and higher doses may be necessary for individuals on a more liberalized diet. 

In individuals with CPS, case reports and small studies indicate that carglumic acid can enhance ureagenesis, reduce ammonia, and significantly improve protein tolerance, particularly in those with residual CPS1 enzyme activity.

L-arginine and L-citrulline supplementation remains a cornerstone of UCD management, tailored based on individual needs and metabolic response. While arginine is essential in CIT-I and ASA, citrulline is preferred for CPS and OTC. Careful monitoring of plasma arginine and citrulline is necessary to avoid deficiency and toxicity. Plasma amino acid concentrations should guide individualized adjustments, and excessive supplementation should be avoided to prevent complications such as hyperargininemia.

Summary
 
Details
Recommendation 4.1

Use Nitrogen Scavengers to Stabilize Biochemical Markers and Improve Protein Tolerance

1. Ensure close coordination between metabolic dietitians and medical providers to individualize scavenger use and titrate protein intake, with regular monitoring of ammonia, plasma amino acids, and dietary intake.

2. Consider initiating or increasing the dose of nitrogen scavengers when higher protein tolerance is indicated.

3. For individuals on an unrestricted diet who consume less protein than the typical American intake (e.g., 97 g/day for adult males and 69 g/day for adult females) and present with clinical or laboratory signs requiring intervention, consider initiating nitrogen scavenger therapy before decreasing protein intake.

Strength of Recommendation:
Insufficient EvidenceConsensusWeakFairStrong
Clinical Action:
ConditionalImperative
Recommendation 4.2

Carglumic Acid to Improve Protein Tolerance in CPS

1. In individuals with CPS, consider using carglumic acid to improve protein tolerance. 

Strength of Recommendation:
Insufficient EvidenceConsensusWeakFairStrong
Clinical Action:
ConditionalImperative
Recommendation 4.3

Provide Amino Acid Supplementation

1. In CPS and OTC, supplement with L-citrulline at 100-200 mg/kg/day divided into several doses to support nitrogen excretion. See TABLE #1, Total Protein and Energy Recommendations for Individuals with Urea Cycle Disorders When Well.

2. In CIT-I and ASA, supplement with L-arginine at approximately 100-300 mg/kg/day for those under 20 kg or 2.5-6 g/m2/day for those over 20 kg, divided into several doses. Consider lower doses in individuals with hepatic dysfunction or mild/late-onset disease, and avoid arginine supplementation in individuals with ARG. See TABLE #1, Total Protein and Energy Recommendations for Individuals with Urea Cycle Disorders When Well.

3. Adjust L-citrulline and L-arginine dosing based on plasma amino acid concentrations to prevent deficiency or toxicity.

Strength of Recommendation:
Insufficient EvidenceConsensusWeakFairStrong
Clinical Action:
ConditionalImperative
About | MNT4P | Genetic Metabolic Dietitians International | Login | Contact